CD8A and acute lymphoblastic leukemia: Moreover, genetic or pharmacologic MERTK inhibition increased the antigen-presentation capacity of CD8+ dendritic cells in a B-ALL model [67] and anti-B-ALL immunity remained partially intact in Mertk-/- mice that had severely diminished CD8+ T cells, implicating an innate immune mechanism [67].